S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
The “Amazon Secret Royalty Program” Can Help Anyone Retire Like Royalty (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
66,000% upside on tiny biotech? (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Oil tanker breaks down in Egypt's Suez Canal, disrupting traffic in the global waterway
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
With oil prices slumping, OPEC+ producers weigh more production cuts
Las Vegas ballpark pitch revives debate over public funding for sports stadiums
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
The “Amazon Secret Royalty Program” Can Help Anyone Retire Like Royalty (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
66,000% upside on tiny biotech? (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Oil tanker breaks down in Egypt's Suez Canal, disrupting traffic in the global waterway
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
With oil prices slumping, OPEC+ producers weigh more production cuts
Las Vegas ballpark pitch revives debate over public funding for sports stadiums
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
The “Amazon Secret Royalty Program” Can Help Anyone Retire Like Royalty (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
66,000% upside on tiny biotech? (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Oil tanker breaks down in Egypt's Suez Canal, disrupting traffic in the global waterway
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
With oil prices slumping, OPEC+ producers weigh more production cuts
Las Vegas ballpark pitch revives debate over public funding for sports stadiums
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
The “Amazon Secret Royalty Program” Can Help Anyone Retire Like Royalty (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
66,000% upside on tiny biotech? (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Oil tanker breaks down in Egypt's Suez Canal, disrupting traffic in the global waterway
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
With oil prices slumping, OPEC+ producers weigh more production cuts
Las Vegas ballpark pitch revives debate over public funding for sports stadiums
NASDAQ:ASND

Ascendis Pharma A/S (ASND) Stock Forecast, Price & News

$91.30
+3.34 (+3.80%)
(As of 06/2/2023 ET)
Compare
Today's Range
$89.17
$91.38
50-Day Range
$69.96
$110.59
52-Week Range
$64.33
$134.52
Volume
264,199 shs
Average Volume
421,255 shs
Market Capitalization
$5.23 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$146.00

Ascendis Pharma A/S MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.73 Rating Score
Upside/​Downside
62.2% Upside
$148.09 Price Target
Short Interest
Bearish
7.73% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.32mentions of Ascendis Pharma A/S in the last 14 days
Based on 12 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($10.55) to ($8.71) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.09 out of 5 stars

Medical Sector

434th out of 983 stocks

Pharmaceutical Preparations Industry

205th out of 486 stocks


ASND stock logo

About Ascendis Pharma A/S (NASDAQ:ASND) Stock

Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. It specializes on its TransCon technologies to create prodrugs that provide for the predictable and sustained release of an unmodified parent drug. The company was founded by Jan Moller Mikkelsen, Dirk Vetter, and Harald Rau in September 2006 and is headquartered in Hellerup, Denmark.

Receive ASND Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ascendis Pharma A/S and its competitors with MarketBeat's FREE daily newsletter.

ASND Stock News Headlines

Ascendis Pharma (ASND) Gets a Buy from Berenberg Bank
How A.I. Could Make Most 21st Century Diseases EXTINCT
On December 22, 2022, AI discovered a new treatment for multiple myeloma... in just 4 months... On March 19, 2023, AI discovered a new drug for liver cancer... in only 30 days... There's one small-cap at the center of it all. Bill Gates owns 7 million shares... Billionaire hedge-fund manager Steve Cohen owns 1.4 million shares...
Ascendis Pharma A/s (NASDAQ: ASND)
Ascendis Pharma (ASND) Receives a Buy from Wedbush
The Latest Analyst Ratings for Ascendis Pharma
Ascendis Pharma (ASND) Receives a Buy from Goldman Sachs
“Amazon Loophole” could hand you $28,544 in “royalty” payouts
Thanks to a little-known IRS loophole… Regular Americans can collect up to $28,544 (or more) in payouts from what Brad Thomas calls the “Amazon secret royalty program…” See how to collect the next payout before the strict cutoff deadline.
Ascendis Shareholder Notice
Ascendis Investor Alert
See More Headlines

ASND Price History

ASND Company Calendar

Last Earnings
4/27/2023
Today
6/03/2023
Next Earnings (Estimated)
8/09/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ASND
Employees
639
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$148.09
High Stock Price Forecast
$187.00
Low Stock Price Forecast
$92.00
Forecasted Upside/Downside
+59.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.73
Research Coverage
11 Analysts

Profitability

Net Income
$-614,450,000.00
Net Margins
-721.72%
Pretax Margin
-720.35%

Debt

Sales & Book Value

Annual Sales
$53.93 million
Book Value
$3.13 per share

Miscellaneous

Free Float
34,397,000
Market Cap
$5.23 billion
Optionable
Optionable
Beta
0.52

Key Executives

  • Jan Møller Mikkelsen
    President, CEO & Executive Director
  • Scott Thomas Smith
    Chief Financial Officer & Senior Vice President
  • Kennett Sprogøe
    Senior Vice President, Head-Innovation & Research
  • Birgitte Volck
    SVP, Head-Clinical Development & Medical Affairs
  • Stina Singel
    Senior Vice President & Head-Clinical Development













ASND Stock - Frequently Asked Questions

Should I buy or sell Ascendis Pharma A/S stock right now?

11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ascendis Pharma A/S in the last year. There are currently 3 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ASND shares.
View ASND analyst ratings
or view top-rated stocks.

What is Ascendis Pharma A/S's stock price forecast for 2023?

11 brokers have issued 12 month price targets for Ascendis Pharma A/S's shares. Their ASND share price forecasts range from $92.00 to $187.00. On average, they expect the company's share price to reach $148.09 in the next year. This suggests a possible upside of 62.2% from the stock's current price.
View analysts price targets for ASND
or view top-rated stocks among Wall Street analysts.

How have ASND shares performed in 2023?

Ascendis Pharma A/S's stock was trading at $122.13 at the start of the year. Since then, ASND shares have decreased by 25.2% and is now trading at $91.30.
View the best growth stocks for 2023 here
.

Are investors shorting Ascendis Pharma A/S?

Ascendis Pharma A/S saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 4,430,000 shares, an increase of 13.6% from the April 30th total of 3,900,000 shares. Based on an average trading volume of 806,600 shares, the short-interest ratio is currently 5.5 days.
View Ascendis Pharma A/S's Short Interest
.

When is Ascendis Pharma A/S's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 9th 2023.
View our ASND earnings forecast
.

How were Ascendis Pharma A/S's earnings last quarter?

Ascendis Pharma A/S (NASDAQ:ASND) issued its quarterly earnings results on Thursday, April, 27th. The biotechnology company reported ($2.12) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($2.84) by $0.72. The biotechnology company had revenue of $36.04 million for the quarter, compared to analysts' expectations of $24.53 million. Ascendis Pharma A/S had a negative trailing twelve-month return on equity of 150.65% and a negative net margin of 721.72%.

What other stocks do shareholders of Ascendis Pharma A/S own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ascendis Pharma A/S investors own include AbbVie (ABBV), Alexion Pharmaceuticals (ALXN), Neurocrine Biosciences (NBIX), ACADIA Pharmaceuticals (ACAD), BioMarin Pharmaceutical (bmrn), Gilead Sciences (GILD), Incyte (INCY), Exelixis (EXEL), GW Pharmaceuticals (GWPH) and NVIDIA (NVDA).

When did Ascendis Pharma A/S IPO?

(ASND) raised $85 million in an IPO on Wednesday, January 28th 2015. The company issued 5,000,000 shares at $16.00-$18.00 per share. BofA Merrill Lynch and Leerink Partners acted as the underwriters for the IPO and Wells Fargo Securities was co-manager.

What is Ascendis Pharma A/S's stock symbol?

Ascendis Pharma A/S trades on the NASDAQ under the ticker symbol "ASND."

Who are Ascendis Pharma A/S's major shareholders?

Ascendis Pharma A/S's stock is owned by a variety of retail and institutional investors. Top institutional investors include Artisan Partners Limited Partnership (11.94%), FMR LLC (8.99%), Price T Rowe Associates Inc. MD (5.88%), Avoro Capital Advisors LLC (5.80%), Westfield Capital Management Co. LP (5.49%) and Wellington Management Group LLP (5.12%).

How do I buy shares of Ascendis Pharma A/S?

Shares of ASND stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ascendis Pharma A/S's stock price today?

One share of ASND stock can currently be purchased for approximately $91.30.

How much money does Ascendis Pharma A/S make?

Ascendis Pharma A/S (NASDAQ:ASND) has a market capitalization of $5.23 billion and generates $53.93 million in revenue each year. The biotechnology company earns $-614,450,000.00 in net income (profit) each year or ($10.49) on an earnings per share basis.

How many employees does Ascendis Pharma A/S have?

The company employs 639 workers across the globe.

How can I contact Ascendis Pharma A/S?

Ascendis Pharma A/S's mailing address is TUBORG BOULEVARD 12, HELLERUP G7, DK-2900. The official website for the company is www.ascendispharma.com. The biotechnology company can be reached via phone at (457) 022-2244, via email at ir@ascendispharma.com, or via fax at 45-3694-4010.

This page (NASDAQ:ASND) was last updated on 6/4/2023 by MarketBeat.com Staff

My Account -